Q1 Earnings Forecast for AUTL Issued By HC Wainwright

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) – Analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for Autolus Therapeutics in a research report issued to clients and investors on Tuesday, February 17th. HC Wainwright analyst E. Bodnar forecasts that the company will post earnings of ($0.28) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Autolus Therapeutics’ current full-year earnings is ($0.94) per share. HC Wainwright also issued estimates for Autolus Therapeutics’ Q4 2026 earnings at ($0.28) EPS, FY2026 earnings at ($1.11) EPS and FY2029 earnings at ($0.42) EPS.

A number of other equities analysts have also recently issued reports on the stock. Needham & Company LLC dropped their price objective on shares of Autolus Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Monday, January 12th. Wall Street Zen lowered shares of Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Saturday, November 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Autolus Therapeutics in a report on Wednesday, January 21st. Finally, Zacks Research lowered Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, January 21st. Five analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat.com, Autolus Therapeutics has an average rating of “Hold” and an average price target of $8.50.

Autolus Therapeutics Price Performance

Shares of AUTL stock opened at $1.56 on Thursday. Autolus Therapeutics has a one year low of $1.11 and a one year high of $2.70. The stock has a fifty day moving average price of $1.57 and a 200 day moving average price of $1.57. The stock has a market cap of $415.18 million, a P/E ratio of -1.88 and a beta of 1.98.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Armistice Capital LLC lifted its position in Autolus Therapeutics by 9.1% during the 2nd quarter. Armistice Capital LLC now owns 12,000,000 shares of the company’s stock worth $27,360,000 after buying an additional 1,000,000 shares in the last quarter. TFG Asset Management GP Ltd increased its position in Autolus Therapeutics by 10.5% in the 2nd quarter. TFG Asset Management GP Ltd now owns 9,500,000 shares of the company’s stock valued at $21,660,000 after acquiring an additional 900,000 shares in the last quarter. Cetera Investment Advisers raised its stake in shares of Autolus Therapeutics by 17.6% in the second quarter. Cetera Investment Advisers now owns 617,172 shares of the company’s stock worth $1,407,000 after acquiring an additional 92,300 shares during the last quarter. R Squared Ltd acquired a new position in shares of Autolus Therapeutics during the second quarter worth approximately $50,000. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of Autolus Therapeutics during the second quarter valued at approximately $1,288,000. 72.83% of the stock is owned by institutional investors and hedge funds.

Autolus Therapeutics News Roundup

Here are the key news stories impacting Autolus Therapeutics this week:

• Positive Sentiment: HC Wainwright initiated coverage with a “Buy”/”Strong-Buy” and a $9.00 price target — a very large implied upside versus the current share price; this kind of initiation can attract momentum buyers and re-rate sentiment for a beaten-down biotech. Read More.
• Positive Sentiment: HC Wainwright published detailed EPS forecasts across FY2025–FY2030 and quarter-level EPS estimates (showing shrinking losses over time), reinforcing their view that Autolus’ pipeline and commercialization path could improve economics over the next several years — supportive for long-term bulls. Read More.
• Neutral Sentiment: Short-interest data for mid-February in the report appears to show zeros/NaN (likely a reporting anomaly) and therefore does not provide clear evidence of elevated short pressure driving the move.
• Negative Sentiment: Risks remain — the $9 target implies very large upside and may be optimistic given current cash burn, clinical/regulatory uncertainties and likely need for future financing; those factors could dilute shareholders or cause volatility if progress stalls.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.